MDT Medtronic Plc

Correction: Medtronic Continuing to Increase Ventilator Production to Address COVID-19 Pandemic

Correction: Medtronic Continuing to Increase Ventilator Production to Address COVID-19 Pandemic

DUBLIN, March 18, 2020 (GLOBE NEWSWIRE) --   (NYSE:MDT), the global leader in medical technology, continues to make progress in increasing ventilator production worldwide. The company has increased production by more than 40 percent to date and is on track to more than double its capacity to manufacture and supply ventilators in response to the urgent needs of patients and healthcare systems across the globe confronting COVID-19.

Medtronic recognizes the acute need for ventilators as life-saving devices in the management of COVID-19 infections. High-performance ventilators play a critical role in the management of patients with severe respiratory illness, such as COVID-19, who require assistance because they cannot breathe effectively. By placing a patient on such a ventilator, the patient’s lungs are permitted to rest and recover while the ventilator performs the functions of supplying oxygen and simulating the actions of breathing. Without ventilation support, some patients with severe respiratory disease might not survive.

Medtronic is an industry leader in respiratory care and device innovation. The company produces high performance ventilators for a variety of care settings, including the acute segment (in-hospital patients in intensive care units, emergency departments or on the general care floors) and the sub-acute segment (out of hospital, long-term care facilities or home-ventilated patients). Medtronic manufactures the Puritan Bennett™ 980 (PB 980) and Puritan Bennett™ 840 (PB 840) high performance ventilators in Galway, Ireland, which are primarily designed for critically ill patients in high acuity setting. A COVID-19 patient (with or without an underlying health issue) could be such a critically ill patient.

Medtronic Demand and Supply

Ventilator demand has significantly increased in light of COVID-19, and Medtronic continues to work to meet this increased global demand. Ventilator manufacturing is a complex process that relies on a skilled workforce, a global supply chain and a rigorous regulatory regime to ensure patient safety.   

In recent weeks, Medtronic has identified additional opportunities to further increase its ventilator manufacturing capacity.  In the company’s Ireland ventilator manufacturing facility, the company currently has over 250 employees dedicated to ventilator manufacturing and plans to more than double that number, including transferring staff from other Medtronic sites to support ramp up activities. Additional manufacturing shifts have been put in place and new manufacturing shift patterns are being introduced to bring the plant to 24/7 operation.  With a strong commitment across Medtronic and its suppliers – combined with the increased staffing – the company expects to be able to more than double its manufacturing capacity for ventilators.  

Medtronic is prioritizing high risk/high needs areas for ventilator allocation on a weekly basis for global distribution through its supply chain. COVID-19 is a dynamic global issue, and Medtronic will continue to monitor the situation and provide updates to its employees, customers and investors as the situation warrants.

“Medtronic recognizes the demand for ventilators in this environment has far outstripped supply,” said Bob White, executive vice president and president of the Minimally Invasive Therapies Group at Medtronic. “No single company will be able to fill the current demands of global healthcare systems. However, with all manufacturers increasing their production and through partnerships with governments, hospitals and global health organizations, Medtronic is committed to getting more ventilators into the market and to the right locations in the world to help doctors and patients dealing with COVID-19.”

About Medtronic

Medtronic plc (), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

John Jordan

Public Relations

Ryan Weispfenning

Investor Relations

EN
19/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medtronic Plc

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Testing Prior Breakout Level DeepSeek appears to have turned the chatbot market upside-down, putting pressure on AI-linked stocks. While the dust has yet to settle, the good news is that the selloff has been largely contained to these AI-linked stocks. The rest of the market did not seem to care; the equal-weighted S&P 500 was roughly flat yesterday. Additionally, market dynamics remain healthy, with Treasury yields, the U.S. dollar (DXY), and WTI crude oil continuing to move lower, and...

Medtronic, Inc.: Update to credit analysis

Our credit view of this issuer reflects its strong product diversification, offset by its large payouts to shareholders.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch